The leading international group in the production of pharmaceutical active ingredients Moehs, member of CATALONIA.HEALTH, has signed an exclusive agreement with EUROAPI to assume the production of Metamizol, the active ingredient of the drug Nolotil, in its facilities in Spain.  

A worldwide leader in specialized diagnostics Werfen, member of CATALONIA. HEALTH, announces the finalization of a partnership agreement with Seegene Inc. Under the agreement, Seegene and Werfen will set up a NewCo in Spain, Werfen-Seegene, upon the conclusion of mandatory government approvals anticipated by the first half of 2025.

The company dedicated to personalized medicine Inbiomotion, member of CATALONIA.HEALTH, have signed an exclusive agreement to start offering the MAF Test® in Italy.

The biopharmaceutical company Oryzon Genomics, member of CATALONIA.HEALTH, announces that it has received the official record of its recent meeting of End-of-Phase II for vafidemstaten for Personality Limit Disorder (TLP) with the US Food and Drug Administration (FDA). ORYZON will begin the preparation of a complete protocol for the study of Phase III PORTICO-2 that will soon be presented to the FDA for approval.  

The UMBRELLA consortium, led by Vall d'Hebron Research Institute (VHIR), a member of CATALONIA.HEALTH, and the company Siemens Healthineers, is made up of more than 20 public and private partners whose objective is to revolutionize the entire stroke care process in Europe.

The biotechnology company Archivel Farma, a member of CATALONIA.HEALTH, announces the opening of a business line as the Contract Development and Manufacturing Organization (CDMO). The initiative will focus on the manufacture of clinical batches under Good Manufacturing Practices (GMP).

The pharmaceutical company Almirall, member of CATALONIA.HEALTH, launches the new Ebglyss treatment (lebrikizumab) in Spain. This monoclonal antibody is already available for the treatment of adult and teen patients with atopic dermatitis from moderate to severe and who are candidates for systemic therapy.  

The “deeptech” and leading bioinformatics company Sequentia Biotech, member of CATALONIA.HEALTH, obtains a €10 million Series A investment, which is led by Seventure Partners, and co-invested by the EIC Fund. The investment will accelerate Sequentia Biotech’s mission to drive innovation in the field of omics.

INBRAIN Neuroelectronics, member of CATALONIA.HEALTH, has announced the world's first application of a graphene interface in a human patient. This intervention was performed on a patient undergoing resection (removal) of a brain tumor. The company is a spin-off of ICN2 and CSIC. 

The pioneering company in the life sciences venture capital sector Asabys Partner, member of CATALONIA.HEALTH, announced today the successful final close of its second fund, Sabadell Asabys Health Innovation Investments II (SAHII II) with total commitments of €180 million ($200M), exceeding its initial target of €150 million.

About twenty professionals from companies and member entities of CATALONIA.HEALTH met this past September 18th, at the Hub Cambra Digital in Barcelona, for the first appointment on the agenda of activities after the summer. It was the fourth edition of this year of the CEO Council sessions with Josep Maria Argimon as a special guest.  

A consortium made up of a group of private and public companies work together to develop the 4D-Bioskin project. Within this group of companies are Biorem, the pharmaceutical company Reig Jofre, University of Barcelona and the Vall d’Hebron Research Institute (VHIR), all members of CATALONIA.HEALTH.

The company specialized in visual and cognitive improvement WIVI Vision, member of CATALONIA.HEALTH, has won the 4th prize in the welfare sector in the first edition of the Impact Social Cup (ISC). It is a competition made up of 8 sectors of large economic activities where entrepreneurs, companies and people highlight their positive impact on society. 

The technology centre Eurecat, a member of CATALONIA.HEALTH, together with the SJD Barcelona Children's Hospital, have designed a social desktop robot, called Robot Jana, to help palliative pediatric patients at home, as it allows remote monitoring of the patient's symptoms and facilitates communication between professionals and the family.

The pharmaceutical company Reig Jofre, a member of CATALONIA.HEALTH, continues its international growth strategy with the opening of a new subsidiary in the Czech Republic, where it already operates through distribution agreements. The new subsidiary will have a sales team specialized in the pharmaceutical market and with the collaboration of a local partner (LERAM Pharma).

The biopharmaceutical AbilityPharma, a member of CATALONIA.HEALTH, has published in BMC Cancer the final data of its phase 1/2 ENDOLUNG trial that evaluates the drug IBRILATAZAR (ABTL0812) in combination with chemotherapy for patients with advanced or recurrent endometrial cancer.

The PERSAM project of IQS, a member of CATALONIA.HEALTH, obtains funding in the program of Knowledge Industry Grants – LLAVOR modality of the AGAUR, an organism of the Generalitat of Catalonia. PERSAM is dedicated to the development of a flexible breathing biosensor for the prevention and monitoring of liver diseases.

Oxolife, member of CATALONIA.HEALTH, has successfully presented the promising results of its Phase 2 study of its new OXO-001 research drug at the 40th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE), held in Amsterdam.   

This August the new government of the Generalitat of Catalonia has been appointed. Two of the new government’s departments will be led by members of CATALONIA.HEALTH. They are Dr. Núria Montserrat, principal investigator and deputy director of translation at the Institute for Bioengineering of Catalonia (IBEC), and Dr. Olga Pané, former manager at Hospital del Mar. 

Integra Therapeutics, member of CATALONIA.HEALTH, will receive a grant of 2.5 million euros and equity investment of up to 8 million euros from the European Commission via the European Innovation Council (EIC) Accelerator program